Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C A Stegeman

Showing results (41-50 of 104) with videos related to

Pageof 11
Sort By:
Annals of the Rheumatic Diseases|April 16, 2009
Thiopurinemethyltransferase (TPMT) genotype and TPMT activity in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: relation to azathioprine maintenance treatment and adverse effectsP M Stassen, R P H Derks, C G M Kallenberg, et al.
Rheumatology (Oxford, England)|March 22, 2008
Venous thromboembolism in ANCA-associated vasculitis--incidence and risk factorsP M Stassen, R P H Derks, C G M Kallenberg, et al.
Arthritis Care & Research|December 14, 2011
Pregnancy in women diagnosed with antineutrophil cytoplasmic antibody-associated vasculitis: outcome for the mother and the childJ Tuin, J S F Sanders, A A E de Joode, et al.
Rheumatology (Oxford, England)|January 10, 2006
Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatmentJ-S F Sanders, M G Huitma, C G M Kallenberg, et al.
Annals of the Rheumatic Diseases|March 1, 2006
Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapseJ-S F Sanders, M G Huitma, C G M Kallenberg, et al.
Nephron. Clinical Practice|November 18, 2014
Pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis and potential targets for biologic treatmentJ S F Sanders, W H Abdulahad, C A Stegeman, et al.
Lupus|August 11, 2006
Quantitation of autoantibodies in systemic autoimmune diseases: clinically useful?C G M Kallenberg, C A Stegeman, H Bootsma, et al.
Kidney International|July 14, 2006
Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosisW H Abdulahad, Y M van der Geld, C A Stegeman, et al.
Lancet (London, England)|April 18, 1998
Lung transplantationJ Broekroelofs, G Navis, C A Stegeman, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 18, 1999
Severe vital depression as the presenting feature of cyclosporin-A-associated thrombotic microangiopathyL R van der Molen, W J van Son, A M Tegzess, et al.
Pageof 11

Showing results (41-50 of 104) with videos related to

Sort By:
Pageof 11
Annals of the Rheumatic Diseases|April 16, 2009
Thiopurinemethyltransferase (TPMT) genotype and TPMT activity in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: relation to azathioprine maintenance treatment and adverse effectsP M Stassen, R P H Derks, C G M Kallenberg, et al.
Rheumatology (Oxford, England)|March 22, 2008
Venous thromboembolism in ANCA-associated vasculitis--incidence and risk factorsP M Stassen, R P H Derks, C G M Kallenberg, et al.
Arthritis Care & Research|December 14, 2011
Pregnancy in women diagnosed with antineutrophil cytoplasmic antibody-associated vasculitis: outcome for the mother and the childJ Tuin, J S F Sanders, A A E de Joode, et al.
Rheumatology (Oxford, England)|January 10, 2006
Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatmentJ-S F Sanders, M G Huitma, C G M Kallenberg, et al.
Annals of the Rheumatic Diseases|March 1, 2006
Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapseJ-S F Sanders, M G Huitma, C G M Kallenberg, et al.
Nephron. Clinical Practice|November 18, 2014
Pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis and potential targets for biologic treatmentJ S F Sanders, W H Abdulahad, C A Stegeman, et al.
Lupus|August 11, 2006
Quantitation of autoantibodies in systemic autoimmune diseases: clinically useful?C G M Kallenberg, C A Stegeman, H Bootsma, et al.
Kidney International|July 14, 2006
Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosisW H Abdulahad, Y M van der Geld, C A Stegeman, et al.
Lancet (London, England)|April 18, 1998
Lung transplantationJ Broekroelofs, G Navis, C A Stegeman, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 18, 1999
Severe vital depression as the presenting feature of cyclosporin-A-associated thrombotic microangiopathyL R van der Molen, W J van Son, A M Tegzess, et al.
Pageof 11